Loki Therapeutics Broadcasts Publication in Science Translational Medication Demonstrating Potential of AWAKE-LM-TT as a Remedy for Pancreatic Most cancers

Novel strategy developed at Albert Einstein School of Medication leverages childhood tetanus vaccination to direct immune system in opposition to pancreatic tumors

LONG ISLAND CITY, N.Y., March 28, 2022 /PRNewswire/ — Loki Therapeutics, an organization growing next-generation therapeutics that leverage vaccination recall antigens to reinforce longevity and deal with immune-system associated illnesses, together with most cancers, in the present day introduced the publications of analysis within the journal, “Science Translational Medication”, demonstrating the potential of AWAKE-LM-TT within the remedy of pancreatic most cancers. AWAKE-LM-TT, which was developed by Claudia Gravekamp, Ph.D., Loki’s Co-Founder and Related Professor of Microbiology & Immunology at Albert Einstein Faculty of Medication, capitalizes on the childhood vaccination for tetanus to generate a robust and instant immune response to strong tumors and metastases presenting the tetanus antigens.

The manuscript titled, “Listeria Delivers Tetanus Toxoid Protein to Pancreatic Tumors and Induces Cancer Cell Death in Mice,” and co-authored by Dr. Gravekamp, Ph.D., describes analysis involving a novel strategy to treating pancreatic most cancers whereby Listeria monocytogenes are used to ship extremely immunogenic tetanus toxoid (TT) proteins immediately into tumor cells. This supply, Listeria-TT, was demonstrated to elicit an immune response, activating tetanus toxoid–particular reminiscence T cells to kill pancreatic ductal adenocarcinoma (PDAC) tumor cells in mice. When mixed with gemcitabine (Listeria-TT + GEM), researchers noticed an 80% discount of PDAC tumor burden and an 87% discount of metastases with an elevated survival by 40% in comparison with nontreated mice, suggesting that Listeria-delivered recall antigens might be an alternative choice to neoantigen-mediated most cancers immunotherapy.

Loki Co-founder and CEO Chris Bradley stated, “This examine is simply the tip of the iceberg relating to figuring out and discovering efficient therapeutics to deal with troublesome cancers. Pancreatic most cancers is troublesome to determine at an early stage, which makes discovering a remedy much more difficult, since it’s often detected at a complicated or late stage. This analysis demonstrates the numerous potential of Loki’s AWAKE-LM-TT as a novel remedy for pancreatic most cancers given its capacity to harness the childhood vaccination for tetanus toxoid to generate a robust and instant immune response to strong tumors and metastases presenting the tetanus antigens.”

Dr. Gravekamp commented, “Due to this analysis, we have now a brand new technique that may not solely be a profitable immunotherapy in treating pancreatic most cancers, however different cancers as properly. Pancreatic tumors are very difficult to deal with in that, to the immune system, these tumors don’t seem sufficiently ‘overseas’ to draw the immune system’s consideration and may often suppress any immune responses that does happen. Our strategy primarily makes these immunologically ‘chilly’ tumors scorching sufficient for the immune system to assault and destroy.”

Story continues

Loki is making ready to file an Investigational New Drug (IND) software with the U.S. Meals & Drug Administration for a first-in-human medical program investigating AWAKE-LM-TT within the remedy of pancreatic most cancers. Upon receiving FDA clearance for the IND, Loki anticipates initiating a Part 1 medical trial within the second half of 2022.

About Loki Therapeutics
Loki Therapeutics is growing next-generation therapeutics that leverage vaccination recall antigens to reinforce longevity and deal with immune-system associated illnesses, together with most cancers, by delivering vaccine recall antigens to tumor cells with genetically attenuated bacterial vectors. Loki’s AWAKE™ platform gives a totally new strategy to treating most cancers and different illnesses attributable to immune-system breakdown by activating and redirecting pre-existing reminiscence T cells created throughout vaccination to focus on and remove most cancers cells, in addition to goal different immune-related illnesses. Key to AWAKE is its utilization of attenuated Listeria Monocytogenes for the exact supply of recall antigens to tumor environments and into the tumor cell. Loki’s lead growth program – AWAKE-LM-TT – capitalizes on the childhood vaccination for tetanus toxoid (TT) to generate an immune response to strong tumors and metastases presenting the tetanus antigens. Loki is at present advancing AWAKE-LM-TT as a possible remedy for metastatic pancreatic most cancers, in addition to metastatic ovarian most cancers. Loki can be pursuing extra growth applications primarily based on different childhood vaccines, together with polio (AWAKE-LM-PV) and mumps. For extra data on Loki Therapeutics please go to www.lokitx.com.

Contacts
Tiberend Strategic Advisors, Inc.

Lisa Sher (Buyers)
[email protected]

Dave Schemelia (media)
[email protected]

View unique content material:https://www.prnewswire.com/news-releases/loki-therapeutics-announces-publication-in-science-translational-medicine-demonstrating-potential-of-awake-lm-tt-as-a-treatment-for-pancreatic-cancer-301510941.html

SOURCE Loki Therapeutics